This trial is active, not recruiting.

Condition osteoporosis
Treatments screening, control
Sponsor Odense University Hospital
Collaborator University of Southern Denmark
Start date January 2010
End date January 2017
Trial size 35000 participants
Trial identifier NCT01388244, ROSE, S-20090127


The Risk-stratified Osteoporosis Strategy Evaluation Study (ROSE) is a randomised population-based study, including 20,904 Danish women aged 65-81 years, investigating the effectiveness of a two-step screening programme for osteoporosis, using a questionnaire based on FRAX® followed by DXA-scan of those at highest risk. Further, the study is expected to provide knowledge about cost-effectiveness, patient preferences and acceptance of screening programme to prevent fractures

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking single blind (subject)
Primary purpose screening
(Active Comparator)
Two-step screening process using FRAX risk score assessment followed by DXA scanning for high risk participants.
screening DXA scan
Screening by risk factor assessment (FRAX) followed by DXA
Control arm - Fracture risk assessment by FRAX without any intervention
Observation by use of register data

Primary Outcomes

The effect of screening for osteoporosis with a two-step programme involving FRAX risk score followed by DXA for the prevention of hip fracture and other osteoporosis-related fracture events
time frame: Three years follow-up on average

Secondary Outcomes

Cost-effectiveness / cost-utility of a two-step screening programme.
time frame: Three years follow-up on average

Eligibility Criteria

Female participants from 65 years up to 80 years old.

Inclusion Criteria: - Women - Age 65-80 years - Inhabitants of the Region of Southern Denmark Exclusion Criteria: - Self-reported use of antiosteoporotic treatment and a diagnose of osteoporosis - Unability to give informed consent

Additional Information

Official title Risk-stratified Osteoporosis Strategy Evaluation Study (ROSE)
Description Osteoporosis is highly prevalent especially in postmenopausal women. Approximately 46 % of all women will suffer at least one osteoporotic fracture after the age of 50. The US Preventive Services Task Force (USPSTF) and National Osteoporosis Foundation (NOF) recommend screening with dual-energy x-ray absorptiometry (DXA) in all women aged 65 years and above regardless of risk factors. Nevertheless, the use of clinical risk factors has been shown to enhance the risk-gradient and accuracy of fracture risk prediction. The FRAX risk assessment score was derived from large population-based cohorts and validated in separate validation cohorts. Its use as a risk assessment tool is endorsed by WHO, but no prospective studies examining the effect of a screening programme using a combination of FRAX and DXA in a two-step manner have been performed previously. 35,000 women aged 65-80 years were selected at random from the population in the Region of Southern Denmark and —before inclusion—randomised to either a screening group or a control group. As first step, a self- administered questionnaire regarding risk factors for osteoporosis based on FRAX® was issued to both groups. As second step, subjects in the screening group with a 10-year probability of major osteoporotic fractures ≥15 % were offered a DXA scan. Patients diagnosed with osteoporosis from the DXA scan were advised to see their GP and discuss pharmaceutical treatment according to Danish National guidelines. The primary outcome is incident clinical fractures as evaluated through annual follow-up using the Danish National Patient Registry. The secondary outcomes are cost-effectiveness, participation rate and patient preferences. The aim of the ROSE study is to investigate the effectiveness of a two-step population based osteoporosis screening programme using FRAX® based on self-administered questionnaire to select women for DXA followed by the standard osteoporosis treatment according to national guidelines and delivered by GPs in the Region of Southern Denmark. Secondary aims are to clarify whether the screening programme is cost-effective and to assess the patients' preferences, experience and acceptance of the screening programme. Moreover, sub-studies allow assessment of the effectiveness of FRAX® alone or combined with individual clinical risk factors in the prediction of fractures and the impact of socioeconomic factors for participation and outcome.
Trial information was received from ClinicalTrials.gov and was last updated in October 2014.
Information provided to ClinicalTrials.gov by Odense University Hospital.